20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup

You are Here : Home > Research

13-May-2024

Cipla

OP up 12.11%

'For the quarter ending March 2024, consolidated net sales (including other operating income) of Cipla has increased 7.39% to Rs 6163.24 crore compared to quarter ended March 2023.  Sales of Phamaceuticals segment has gone up 8.31% to Rs 5,996.38 crore (accounting for 96.57% of total sales).  Sales of New Ventures segment has gone down 8.91% to Rs 212.99 crore (accounting for 3.43% of total sales).  Inter-segment sales rose Rs 30.89 crore to Rs 46.13 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 32.71% to Rs 1,276.85 crore.  PBIT of Phamaceuticals segment rose 30.35% to Rs 1,322.45 crore (accounting for 103.57% of total PBIT).  PBIT of New Ventures segment rose 13.01% to Rs -45.60 crore (accounting for -3.57% of total PBIT).  

PBIT margin of Phamaceuticals segment rose from 18.33% to 22.05%.  PBIT margin of New Ventures segment rose from negative 22.42% t...



Pleaselogin & subscribe to view the full report.

More Reports
More Reports View Company Information

  • Results-Analysis   (30-Oct-2024)

    Cipla

    NP up 15.18%

  • Results-Analysis   (27-Jul-2024)

    Cipla

    OP increased 14.85%

  • Results-Analysis   (13-May-2024)

    Cipla

    OP up 12.11%

  • Results-Analysis   (23-Jan-2024)

    Cipla

    NP up 31.83%